Managed Access Programs for VAY736, Ianalumab
Latest Information Update: 18 Dec 2025
At a glance
- Drugs Ianalumab (Primary)
- Indications Sjogren's syndrome; Thrombocytopenia
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 09 Dec 2025 Status changed from suspended to recruiting.
- 02 Dec 2025 New trial record